Myriad Genetics Faces Securities Probe Following Revenue Guidance Cut

A sharp pivot in financial outlook has triggered a securities investigation into Myriad Genetics, following a second-quarter revenue miss and a dramatic $90 million reduction in full-year guidance. Investors are now scrutinizing whether previous management disclosures regarding the company’s revenue and EBITDA targets were materially misleading.

Money Talk·August 10, 2026·reads: 2,034

Myriad Genetics reported Q2 2026 revenue of $190.7 million, falling significantly short of the anticipated $206-208 million range. The company, which had reiterated its bullish $860-880 million annual revenue forecast as recently as May 5, slashed that projection to $770-790 million just three months later. Alongside the top-line revision, the firm suspended its adjusted EBITDA guidance entirely, citing systemic pressure from collections, reimbursement hurdles, and underperformance in prenatal testing.

Legal firm Levi & Korsinsky has launched an investigation into potential violations of federal securities laws. The inquiry focuses on whether the company’s internal projections and statements to shareholders accurately reflected the underlying health of its testing business. Investors who suffered losses during this period are being evaluated for potential claims, with the firm emphasizing that eligibility for participation does not depend on current share ownership.